#Spain #Madrid #pharmaceuticals #Suanfarma #Pere Mañé

Pere Mañé Takes Leadership Role at Suanfarma

Recently, Suanfarma, a key player in the pharmaceutical industry known for developing and manufacturing active pharmaceutical ingredients (APIs), made headlines with the announcement of Pere Mañé Godina as its new Chief Executive Officer (CEO). This appointment marks a pivotal moment for the company as it embarks on a path toward industrial consolidation, innovation, and global expansion.

A Seasoned Executive with Rich Experience

Pere Mañé brings over three decades of extensive experience in the pharmaceutical sector, having held various technical and strategic leadership roles in prominent companies like Uquifa, Boehringer Ingelheim, and Esteve Química. His previous positions ranged from general manager to the Group Chief Industrial Operations Officer, showcasing his diverse skill set in management and operational roles. Notably, during his tenure at Esteve, Mañé played a pivotal role in industrial transformation, positioning the chemical division as a global leader and earning recognition as the 2025 CDMO of the Year for Small Molecules at the prestigious DCAT Leadership Awards.

Vision for the Future

Mañé's appointment aligns perfectly with Suanfarma's long-term strategic goals. Carlos Alonso, who has served as the interim CEO since October 2024, will ensure a smooth transition and will continue to contribute as Executive Chairman. In light of Mañé's extensive industry knowledge and strategic mindset, there’s a shared confidence that his leadership will further strengthen Suanfarma's market position while providing high-quality solutions to clients and partners.

“Pere’s arrival brings a crucial momentum to Suanfarma's growth trajectory,” said Alonso. His focus on operational excellence, advanced CDMO capabilities, and robust strategic partnerships is expected to guide the company through the next phase of its development.

Immediate Goals and Aspirations

Moving forward, Pere Mañé has defined several key objectives:

• - Streamline industrial processes and integrate new technologies for improved efficiency.
• - Strengthen relations with global customers and key suppliers to foster collaborative growth.
• - Accelerate international expansion to tap into new markets.
• - Promote a culture of innovation and sustainability throughout the organization.

In his own words, Pere Mañé expressed optimism about Suanfarma's future: “The company is well-positioned to lead the industry with its solid foundation, strong industrial platform, and a high-quality international network, backed by an exceptional team. I am excited to begin this new chapter and work collaboratively to continue offering our customers innovative, efficient, and sustainable solutions.”

About Suanfarma

Founded in 1993, Suanfarma has established itself as a B2B partner in the life sciences sector. The company is dedicated to the sustainable development, manufacturing, and distribution of high-quality pharmaceutical ingredients aimed at fostering health and innovation. Present in over 70 countries, Suanfarma became part of the healthcare-focused investment firm Archimed in 2021. As Mañé takes the helm, all eyes are on how Suanfarma will evolve under his leadership, navigating the complexities of a rapidly changing pharmaceutical landscape while remaining committed to quality and innovation.